U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18ClN5
Molecular Weight 351.833
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADINAZOLAM

SMILES

CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=GJSLOMWRLALDCT-UHFFFAOYSA-N
InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C19H18ClN5
Molecular Weight 351.833
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Adinazolam, a benzodiazepine agonist, is an effective anxiolytic agent with antidepressant properties. It was shown, that adinazolam by itself had relatively weak benzodiazepine agonist activity, and much of the pharmacological activity belonged to its active metabolite N-desmethyladinazolam (NDMAD). Adinazolam has never been FDA approved, but it is sold as a research chemical.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
PubMed

PubMed

TitleDatePubMed
Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine.
1983 Nov
Determination of biological activity of adinazolam and its metabolites.
1984 Aug
Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites.
1985 Oct 24
The effects of chronic antidepressant treatment in an animal model of anxiety.
1988
Inhibition of the binding and the behavioral effects of thyrotropin-releasing hormone (TRH) by the triazolobenzodiazepines.
1988 May
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.
1989 Feb
The early acquisition of two-way (shuttle-box) avoidance as an anxiety-mediated behavior: psychopharmacological validation.
1991 Jan
Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment.
1991 Nov
Platelet alpha-2 adrenoreceptor activity pre-treatment and post-treatment in major depressive disorder with melancholia.
1991 Oct
Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.
1992 Aug
Benzodiazepine suppression of corticotropin-releasing factor (CRF)-induced beta-endorphin release from rat neurointermediate pituitary.
1992 Sep-Oct
Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.
1993
Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia.
1993 Aug
Flumazenil prevents the anxiolytic effects of diazepam, alprazolam and adinazolam on the early acquisition of two-way active avoidance.
1993 Jul-Aug
Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
1998 Mar
A follow-up study of DSM-III-R generalized anxiety disorder with syndromal and subsyndromal major depression.
2003 Feb
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.
2003 Feb 28
Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.
2005 May
Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
2007 Jul
The effect of sympathetic antagonists on the antidepressant action of alprazolam.
2008 Jun 1
The enduring effects of an adolescent social stressor on synaptic density, part II: Poststress reversal of synaptic loss in the cortex by adinazolam and MK-801.
2008 Mar
Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.
2009 Jun
Recent trends in the impurity profile of pharmaceuticals.
2010 Jul
Patents

Patents

Sample Use Guides

from 90 to 40 mg/day.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:45:49 GMT 2023
Edited
by admin
on Sat Dec 16 17:45:49 GMT 2023
Record UNII
KN08449444
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADINAZOLAM
INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
ADINAZOLAM [MI]
Common Name English
U-41,123
Code English
Adinazolam [WHO-DD]
Common Name English
4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-1-METHANAMINE, 8-CHLORO-N-N-DIMETHYL-6-PHENYL-
Common Name English
U-41123
Code English
adinazolam [INN]
Common Name English
8-Chloro-1-[(dimethylamino)methyl]-6-phenyl-4H-S-triazolo[4,3-a][1,4]benzodiazepine
Systematic Name English
ADINAZOLAM [USAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05BA07
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
NCI_THESAURUS C1012
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
WHO-ATC N05BA07
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
WIKIPEDIA Designer-drugs-Adinazolam
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
Code System Code Type Description
FDA UNII
KN08449444
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
PUBCHEM
37632
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID40190611
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
WIKIPEDIA
ADINAZOLAM
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
SMS_ID
100000087684
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
DRUG CENTRAL
93
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
NCI_THESAURUS
C76531
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL328250
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
MERCK INDEX
m1418
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY Merck Index
INN
4996
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
EVMPD
SUB05271MIG
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
MESH
C039668
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
CHEBI
251412
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
DRUG BANK
DB00546
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
CAS
37115-32-5
Created by admin on Sat Dec 16 17:45:50 GMT 2023 , Edited by admin on Sat Dec 16 17:45:50 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY